



ASX Release  
2 December 2021

ASX Code: MEM

## **FIELD DATA COLLECTION SUCCESSFULLY COMPLETED USING THE PROTOTYPE SAMSON STALLION FERTILITY DIAGNOSTIC DEVICE**

### **Highlights**

- Trial was conducted in NSW at a thoroughbred and standardbred horse stud.
- Pregnancy outcome data and mare parameters now being collated by University of Newcastle researchers on ~240 inseminations across the two studs
- Results on the pregnancy predictive power of the Samson technology anticipated in 1Q CY22

Australian-based bio-separations and reproductive biotechnology company Memphasys Limited (ASX: MEM) ("Memphasys" or "the Company") is pleased to announce completion of field trial data collection by University of Newcastle researchers on its novel prototype SAMSON stallion fertility diagnostic device.

Data on ~240 mare inseminations was collected from two NSW equine studs during the horse breeding season in October and November 2021. Data on the mare and the pregnancy outcome is now being collated.

### **About SAMSON<sup>1</sup>**

The SAMSON device is being tested for use in the breeding shed within 15 minutes of stallion ejaculation to provide a measure of the quality of the semen and a prediction of the likelihood that the semen will achieve a pregnancy in the inseminated mare.

The field trial data combined with pregnancy outcome and previous individual mare and stallion breeding statistics is being analysed by the University of Newcastle to determine the accuracy of the device to predict mare pregnancy. If a positive predictive correlation is achieved, a SAMSON pregnancy prediction algorithm for the specific stallion and mare pairing will be developed and a final commercial device will be built in preparation for use in the next breeding season.

**This announcement has been approved for release by the board of Memphasys Limited.**

**ENDS**

### **For further information please contact:**

Alison Coutts  
Executive Chairman  
Memphasys Limited  
T: +61 2 8415 7300  
E: [alison.coutts@memphasys.com](mailto:alison.coutts@memphasys.com)

David Tasker  
Managing Director  
Chapter One Advisors  
T: +0433 112 936  
E: [dtasker@chapteroneadvisors.com.au](mailto:dtasker@chapteroneadvisors.com.au)

<sup>1</sup> Refer to ASX announcement dated 20<sup>th</sup> September 2021

**About Memphasys:**

Memphasys Limited (**ASX: MEM**) specialises in biological separations and reproductive biotechnology for high value commercial applications.

Reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media.

The Company's patented bio-separation technology, utilised by the Company's most advanced product, the Felix™ device, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.

Website: [www.memphasys.com](http://www.memphasys.com)